238 related articles for article (PubMed ID: 16487224)
1. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.
Uno T; Shimizu M; Yasui-Furukori N; Sugawara K; Tateishi T
Br J Clin Pharmacol; 2006 Mar; 61(3):309-14. PubMed ID: 16487224
[TBL] [Abstract][Full Text] [Related]
2. Effects of clarithromycin and verapamil on rabeprazole pharmacokinetics between CYP2C19 genotypes.
Shimizu M; Uno T; Yasui-Furukori N; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Aug; 62(8):597-603. PubMed ID: 16783561
[TBL] [Abstract][Full Text] [Related]
3. Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes.
Yasui-Furukori N; Takahata T; Nakagami T; Yoshiya G; Inoue Y; Kaneko S; Tateishi T
Br J Clin Pharmacol; 2004 Apr; 57(4):487-94. PubMed ID: 15025747
[TBL] [Abstract][Full Text] [Related]
4. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes.
Yasui-Furukori N; Saito M; Uno T; Takahata T; Sugawara K; Tateishi T
J Clin Pharmacol; 2004 Nov; 44(11):1223-9. PubMed ID: 15496639
[TBL] [Abstract][Full Text] [Related]
5. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes.
Saito M; Yasui-Furukori N; Uno T; Takahata T; Sugawara K; Munakata A; Tateishi T
Br J Clin Pharmacol; 2005 Mar; 59(3):302-9. PubMed ID: 15752376
[TBL] [Abstract][Full Text] [Related]
6. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes.
Miura M; Kagaya H; Tada H; Uno T; Yasui-Furukori N; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2006 Mar; 61(3):315-20. PubMed ID: 16487225
[TBL] [Abstract][Full Text] [Related]
7. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
[TBL] [Abstract][Full Text] [Related]
8. Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve.
Niioka T; Uno T; Yasui-Furukori N; Shimizu M; Sugawara K; Tateishi T
Eur J Clin Pharmacol; 2006 Oct; 62(10):855-61. PubMed ID: 16915367
[TBL] [Abstract][Full Text] [Related]
9. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
10. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
[TBL] [Abstract][Full Text] [Related]
11. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.
Sakai T; Aoyama N; Kita T; Sakaeda T; Nishiguchi K; Nishitora Y; Hohda T; Sirasaka D; Tamura T; Tanigawara Y; Kasuga M; Okumura K
Pharm Res; 2001 Jun; 18(6):721-7. PubMed ID: 11474773
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism.
Ieiri I; Kishimoto Y; Okochi H; Momiyama K; Morita T; Kitano M; Morisawa T; Fukushima Y; Nakagawa K; Hasegawa J; Otsubo K; Ishizaki T
Eur J Clin Pharmacol; 2001 Sep; 57(6-7):485-92. PubMed ID: 11699613
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
Hu YM; Xu JM; Mei Q; Xu XH; Xu SY
Acta Pharmacol Sin; 2005 Mar; 26(3):384-8. PubMed ID: 15715938
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.
Shirai N; Furuta T; Moriyama Y; Okochi H; Kobayashi K; Takashima M; Xiao F; Kosuge K; Nakagawa K; Hanai H; Chiba K; Ohashi K; Ishizaki T
Aliment Pharmacol Ther; 2001 Dec; 15(12):1929-37. PubMed ID: 11736724
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
Adachi K; Katsube T; Kawamura A; Takashima T; Yuki M; Amano K; Ishihara S; Fukuda R; Watanabe M; Kinoshita Y
Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers.
Lin CJ; Yang JC; Uang YS; Chern HD; Wang TH
Pharmacotherapy; 2003 Jun; 23(6):711-9. PubMed ID: 12820812
[TBL] [Abstract][Full Text] [Related]
20. Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
Yasumori T; Narita H; Matsuda T; Takubo T; Ogawa M; Ishii M; Hara K; Ishii Y; Okuyama K; Fujimoto G; Ochiai H; Kano A; Hasegawa S; Sato K; Taniguchi T
Eur J Clin Pharmacol; 2006 Nov; 62(11):939-46. PubMed ID: 16953457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
